BioSpace News Archive

Novocure (NASDAQ: NVCR) announced today that it will report financial results for the second quarter 2020 on Thursday, July 30, 2020, before the U.S. financial markets open. Novocure’s management will host a conference call and webcast to discuss its financial results for the three and six months ended June 30, 2020, at 8 a.m. EDT on Thursday, July 30, 2020. Analysts and investors can participate in the conference call b

AdaptHealth Corp. (NASDAQ: AHCO) (“AdaptHealth” or the “Company”), a leading provider of home medical equipment, supplies and related services in the United States, announced today the upsizing and pricing of its previously announced underwritten public offering of 8,000,000 shares of its Class A Common Stock at a price to the public of $15.50 per share.

In response to the growing cell and gene therapy demand in the Philadelphia region, MRA Group (MRA) is pressing onward to deliver by year end, two specialized multi-tenant life science lab buildings: a 65,000+/-SF lab building in the city of Philadelphia and a 72,000+/-SF lab building at Spring House Innovation Park, just outside the city.

eGenesis, a biotechnology company using breakthrough gene editing technologies for the development of safe and effective human-compatible organs, tissues, and cells to address the global organ shortage, today announced that Peter Hanson, DVM, Ph.D., has been appointed as Chief Operating Officer (COO). Dr. Hanson will assume responsibility for directing eGenesis’ day-to-day organizational and operational activities including production and man

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in patients with narcolepsy, today announced the sale of its portfolio of sterile injectable drugs used in the hospital setting, including three commercial products, Bloxiverz ® , Vazculep ® , and Akovaz ® , as well as Nouress™, which is approved

Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexant Corporate focus now on lead product, roluperidone, in Phase 3 development WALTHAM, Mass., July 01, 2020 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, announ

SOTIO , a clinical stage immuno-oncology company owned by PPF Group, today announced the appointment of Richard Sachse, M.D., Ph.D., as chief medical officer effective July 1, 2020. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and scientist and was most recently the deputy chief medical officer of SOTIO. “Dr. Sachse has professional expertise in pharmaceutical development covering

X4 Pharmaceuticals, Inc., a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, announced that, on June 30, 2020, the Compensation Committee of X4’s Board of Directors issued an inducement award to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan.

- Phase 2b CONTROL study is evaluating TMB-001 (topical isotretinoin) in subtypes of rare genetic keratinization disorder - - Company also advancing Phase 2b clinical trial evaluating TMB-002 (topical rapamycin) for treatment of facial angiofibromas in tuberous sclerosis complex with 70% of trial sites now open - WOODCLIFF LAKE, N.J., July 01, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Timber Pharmaceuticals, Inc. (“Timber” or the “Company”) (NYSE American: TMBR), a biopharmaceutical co

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designations for setmelanotide, an investigational melanocortin-4 receptor (MC4R) agonist, for the treatment of pro-opiomelanocortin (POMC) deficiency obesity and lept